MIST stock forecast, quote, news & analysis
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines... Show more
Milestone Pharmaceuticals (MIST) Stock Analysis: CARDAMYST Launch Momentum and the AFib-RVR Expansion Path
Key Takeaways
- MIST shares have risen roughly 7% over the trailing 30 days, from a close near $0.71 to about $0.76, though the stock remains well below levels reached earlier in 2026.
- Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company focused on cardiovascular medicines, led by its FDA-approved CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT).
- The mid-February 2026 commercial launch of CARDAMYST is the central investment narrative, with prescriptions, unique prescribers, and payer coverage all expanding through the first half of the year.
- A pivotal Phase 3 program (ReVeRA-301) evaluating etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) targets a substantially larger patient population and is now enrolling participants.
- The company reported about $170.6 million in cash and investments as of mid-2026, with an expected runway into the second half of 2027.
- For additional detail on valuation and expectations, explore Milestone's Price Targets, Earnings, and Forecast pages.
- For automated, data-driven trading ideas across the market, explore Trending AI Robots.
Current Market Snapshot
Milestone Pharmaceuticals (MIST) has traded in a relatively narrow range in recent weeks, with the stock moving from a close near $0.71 in early October to about $0.76, a gain of roughly 7% over the trailing 30 days. That modest recovery follows a broader pullback from the higher levels the shares reached earlier in 2026, when investor enthusiasm around the CARDAMYST launch pushed the stock considerably above its current price.
Sentiment remains tied to the early commercial traction of CARDAMYST and to clinical milestones in the AFib-RVR program. As a small-cap, pre-profitability biotech in an active launch phase, MIST continues to attract attention primarily from specialists and growth-oriented investors tracking prescription trends, payer coverage decisions, and regulatory timelines rather than near-term earnings.
Milestone Pharmaceuticals (MIST) Business Overview and Competitive Position
Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, is a calcium channel blocker approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. The product is designed as a self-administered, rapid-response therapy that patients can use outside a healthcare setting, addressing an unmet need in a market that had seen little therapeutic innovation for decades.
Beyond its approved indication, Milestone is developing etripamil in a Phase 3 registrational trial (ReVeRA-301) for AFib-RVR and in earlier-stage work for pediatric PSVT. The company's competitive positioning rests on its first-mover status in self-administered acute tachycardia care, an established calcium channel blocker mechanism, and a broad clinical dataset supporting CARDAMYST. Investors follow MIST closely because the trajectory of the CARDAMYST launch and the expansion into AFib-RVR define both near-term revenue potential and the long-term value of the franchise.
Recent Developments Driving MIST
The dominant driver of MIST's narrative over recent months has been the execution of the CARDAMYST launch. Management reported more than 1,500 total prescriptions filled for over 1,300 patients through the first half of 2026, with more than 800 unique prescribers. Commercial coverage expanded meaningfully after the second quarter, crossing approximately 50% of commercially insured lives following formulary wins with UnitedHealthcare and other plans using Express Scripts or Optum Rx.
On the clinical and regulatory front, Milestone announced in early September 2026 that China's National Medical Products Administration had approved etripamil nasal spray for PSVT, marking the first approval outside the United States and triggering a $2.0 million milestone payment under the company's partnership with Everest Medicines. The company has also begun enrolling the ReVeRA-301 Phase 3 trial for AFib-RVR, with the first Canadian and European participants announced in late September and early October 2026, and presented new data at the AHA Scientific Sessions 2026 showing CARDAMYST converted recurrent PSVT in patients with prior catheter ablation.
Analyst activity has remained generally constructive. Raymond James lowered its price target to $5 from $6 in October 2026 while maintaining a Strong Buy rating, citing improving payer coverage and encouraging prescription growth. Piper Sandler has reiterated a Buy rating with a higher target. These developments have supported sentiment even as the company continues to report widening net losses associated with launch-related spending.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that actively trade thousands of tickers, but only the top-performing and most relevant strategies surface in its curated Trending AI Robots section. The bots featured there vary in strategy, timeframe, and performance metrics, ranging from short-term momentum systems to longer-horizon swing approaches, each driven by algorithmic analysis of price action, technical signals, and market data. For investors seeking a systematic, data-driven complement to their own research, browsing this section can offer a useful view of which automated strategies are currently demonstrating strength across the broader market.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important near-term catalysts include the company's third-quarter 2026 financial results, scheduled for mid-November 2026, which will provide updated prescription, prescriber, coverage, and revenue figures for the CARDAMYST launch. Continued expansion of commercial and Medicare coverage, as well as average selling price and gross-to-net trends, will be closely watched indicators of whether early adoption is translating into meaningful revenue.
On the pipeline side, progress in the ReVeRA-301 Phase 3 trial for AFib-RVR and the expected decision from the European Medicines Agency on etripamil for PSVT in the first half of 2027 are key value-driving milestones. Investors should also monitor cash burn against the company's projected runway into the second half of 2027, competitive dynamics in the cardiology space, and any additional analyst ratings or price target revisions. These factors, rather than near-term earnings, are likely to shape sentiment around MIST through 2026 and into 2027.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIST's RSI Indicator climbs out of oversold territory
The RSI Indicator for MIST moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 29 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 57 cases where MIST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology